1	Bristol-Myers	_	NNP	_	_	2	NAME	_	_
2	Squibb	_	NNP	_	_	16	SBJ	_	_
3	Co.	_	NNP	_	_	2	POSTHON	_	_
4	,	_	,	_	_	2	P	_	_
5	New	_	NNP	_	_	6	NAME	_	_
6	York	_	NNP	_	_	2	LOC	_	_
7	,	_	,	_	_	2	P	_	_
8	the	_	DT	_	_	11	NMOD	_	_
9	newly	_	RB	_	_	10	AMOD	_	_
10	merged	_	VBN	_	_	11	NMOD	_	_
11	drug	_	NN	_	_	2	APPO	_	_
12	and	_	CC	_	_	11	COORD	_	_
13	health-care-product	_	NN	_	_	14	NMOD	_	_
14	company	_	NN	_	_	12	CONJ	_	_
15	,	_	,	_	_	2	P	_	_
16	reported	_	VBD	_	_	0	ROOT	_	_
17	record	_	NN	_	_	19	NMOD	_	_
18	third-quarter	_	NN	_	_	19	NMOD	_	_
19	earnings	_	NNS	_	_	16	OBJ	_	_
20	for	_	IN	_	_	19	NMOD	_	_
21	both	_	DT	_	_	22	NMOD	_	_
22	companies	_	NNS	_	_	20	PMOD	_	_
23	in	_	IN	_	_	22	LOC	_	_
24	the	_	DT	_	_	25	NMOD	_	_
25	merger	_	NN	_	_	23	PMOD	_	_
26	.	_	.	_	_	16	P	_	_

1	Bristol-Myers	_	NNP	_	_	11	SBJ	_	_
2	Co.	_	NNP	_	_	1	POSTHON	_	_
3	and	_	CC	_	_	1	COORD	_	_
4	Squibb	_	NNP	_	_	3	CONJ	_	_
5	Corp.	_	NNP	_	_	4	POSTHON	_	_
6	,	_	,	_	_	4	P	_	_
7	Princeton	_	NNP	_	_	4	LOC	_	_
8	,	_	,	_	_	7	P	_	_
9	N.J.	_	NNP	_	_	7	APPO	_	_
10	,	_	,	_	_	7	P	_	_
11	merged	_	VBD	_	_	0	ROOT	_	_
12	Oct.	_	NNP	_	_	11	TMP	_	_
13	4	_	CD	_	_	12	NMOD	_	_
14	,	_	,	_	_	11	P	_	_
15	but	_	CC	_	_	11	COORD	_	_
16	the	_	DT	_	_	18	NMOD	_	_
17	new	_	JJ	_	_	18	NMOD	_	_
18	company	_	NN	_	_	19	SBJ	_	_
19	reported	_	VBD	_	_	15	CONJ	_	_
20	third-period	_	JJ	_	_	21	NMOD	_	_
21	earnings	_	NNS	_	_	19	OBJ	_	_
22	for	_	IN	_	_	21	NMOD	_	_
23	both	_	DT	_	_	24	NMOD	_	_
24	companies	_	NNS	_	_	22	PMOD	_	_
25	.	_	.	_	_	11	P	_	_

1	For	_	IN	_	_	8	TMP	_	_
2	the	_	DT	_	_	4	NMOD	_	_
3	fourth	_	JJ	_	_	4	NMOD	_	_
4	quarter	_	NN	_	_	1	PMOD	_	_
5	,	_	,	_	_	8	P	_	_
6	Bristol-Myers	_	NNP	_	_	7	NAME	_	_
7	Squibb	_	NNP	_	_	8	SBJ	_	_
8	will	_	MD	_	_	0	ROOT	_	_
9	report	_	VB	_	_	8	VC	_	_
10	one	_	CD	_	_	11	NMOD	_	_
11	set	_	NN	_	_	9	OBJ	_	_
12	of	_	IN	_	_	11	NMOD	_	_
13	earnings	_	NNS	_	_	12	PMOD	_	_
14	.	_	.	_	_	8	P	_	_

1	Bristol-Myers	_	NNP	_	_	2	SBJ	_	_
2	said	_	VBD	_	_	0	ROOT	_	_
3	net	_	JJ	_	_	4	NMOD	_	_
4	income	_	NN	_	_	5	SBJ	_	_
5	rose	_	VBD	_	_	2	OBJ	_	_
6	15	_	CD	_	_	7	NMOD	_	_
7	%	_	NN	_	_	5	EXT	_	_
8	to	_	TO	_	_	5	DIR	_	_
9	$	_	$	_	_	8	PMOD	_	_
10	266.2	_	CD	_	_	9	DEP	_	_
11	million	_	CD	_	_	9	DEP	_	_
12	,	_	,	_	_	9	P	_	_
13	or	_	CC	_	_	9	COORD	_	_
14	93	_	CD	_	_	15	NMOD	_	_
15	cents	_	NNS	_	_	13	CONJ	_	_
16	a	_	DT	_	_	17	NMOD	_	_
17	share	_	NN	_	_	15	ADV	_	_
18	,	_	,	_	_	9	P	_	_
19	from	_	IN	_	_	5	DIR	_	_
20	$	_	$	_	_	19	PMOD	_	_
21	232.3	_	CD	_	_	20	DEP	_	_
22	million	_	CD	_	_	20	DEP	_	_
23	,	_	,	_	_	20	P	_	_
24	or	_	CC	_	_	20	COORD	_	_
25	81	_	CD	_	_	26	NMOD	_	_
26	cents	_	NNS	_	_	24	CONJ	_	_
27	a	_	DT	_	_	28	NMOD	_	_
28	share	_	NN	_	_	26	ADV	_	_
29	,	_	,	_	_	20	P	_	_
30	a	_	DT	_	_	31	NMOD	_	_
31	year	_	NN	_	_	32	AMOD	_	_
32	earlier	_	RBR	_	_	19	TMP	_	_
33	.	_	.	_	_	2	P	_	_

1	Sales	_	NNS	_	_	2	SBJ	_	_
2	gained	_	VBD	_	_	0	ROOT	_	_
3	5	_	CD	_	_	4	NMOD	_	_
4	%	_	NN	_	_	2	OBJ	_	_
5	to	_	TO	_	_	2	DIR	_	_
6	$	_	$	_	_	5	PMOD	_	_
7	1.59	_	CD	_	_	6	DEP	_	_
8	billion	_	CD	_	_	6	DEP	_	_
9	from	_	IN	_	_	2	DIR	_	_
10	$	_	$	_	_	9	PMOD	_	_
11	1.52	_	CD	_	_	10	DEP	_	_
12	billion	_	CD	_	_	10	DEP	_	_
13	.	_	.	_	_	2	P	_	_

1	Squibb	_	NNP	_	_	3	SBJ	_	_
2	Corp.	_	NNP	_	_	1	POSTHON	_	_
3	said	_	VBD	_	_	0	ROOT	_	_
4	net	_	NN	_	_	5	SBJ	_	_
5	rose	_	VBD	_	_	3	OBJ	_	_
6	17	_	CD	_	_	7	NMOD	_	_
7	%	_	NN	_	_	5	EXT	_	_
8	to	_	TO	_	_	5	DIR	_	_
9	$	_	$	_	_	8	PMOD	_	_
10	144.5	_	CD	_	_	9	DEP	_	_
11	million	_	CD	_	_	9	DEP	_	_
12	,	_	,	_	_	9	P	_	_
13	or	_	CC	_	_	9	COORD	_	_
14	$	_	$	_	_	13	CONJ	_	_
15	1.47	_	CD	_	_	14	NMOD	_	_
16	a	_	DT	_	_	17	NMOD	_	_
17	share	_	NN	_	_	14	ADV	_	_
18	,	_	,	_	_	9	P	_	_
19	from	_	IN	_	_	5	DIR	_	_
20	$	_	$	_	_	19	PMOD	_	_
21	123	_	CD	_	_	20	DEP	_	_
22	million	_	CD	_	_	20	DEP	_	_
23	,	_	,	_	_	20	P	_	_
24	or	_	CC	_	_	20	COORD	_	_
25	$	_	$	_	_	24	CONJ	_	_
26	1.25	_	CD	_	_	25	NMOD	_	_
27	a	_	DT	_	_	28	NMOD	_	_
28	share	_	NN	_	_	25	ADV	_	_
29	.	_	.	_	_	3	P	_	_

1	Sales	_	NNS	_	_	2	SBJ	_	_
2	were	_	VBD	_	_	0	ROOT	_	_
3	$	_	$	_	_	2	PRD	_	_
4	730.1	_	CD	_	_	3	DEP	_	_
5	million	_	CD	_	_	3	DEP	_	_
6	,	_	,	_	_	2	P	_	_
7	up	_	IN	_	_	2	ADV	_	_
8	7	_	CD	_	_	9	NMOD	_	_
9	%	_	NN	_	_	7	AMOD	_	_
10	from	_	IN	_	_	7	AMOD	_	_
11	$	_	$	_	_	10	PMOD	_	_
12	679.5	_	CD	_	_	11	DEP	_	_
13	million	_	CD	_	_	11	DEP	_	_
14	.	_	.	_	_	2	P	_	_

1	In	_	IN	_	_	11	LOC	_	_
2	New	_	NNP	_	_	7	NMOD	_	_
3	York	_	NNP	_	_	7	NMOD	_	_
4	Stock	_	NNP	_	_	7	NMOD	_	_
5	Exchange	_	NNP	_	_	7	NMOD	_	_
6	composite	_	JJ	_	_	7	NMOD	_	_
7	trading	_	NN	_	_	1	PMOD	_	_
8	,	_	,	_	_	11	P	_	_
9	Bristol-Myers	_	NNP	_	_	10	NAME	_	_
10	Squibb	_	NNP	_	_	11	SBJ	_	_
11	rose	_	VBD	_	_	0	ROOT	_	_
12	$	_	$	_	_	11	EXT	_	_
13	1.75	_	CD	_	_	12	NMOD	_	_
14	to	_	TO	_	_	11	DIR	_	_
15	$	_	$	_	_	14	PMOD	_	_
16	52.75	_	CD	_	_	15	NMOD	_	_
17	.	_	.	_	_	11	P	_	_

